TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03647917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands.
Study: NCT03634735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine
Description: Vitamine B1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT00867919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Family Treatment
Description: 11 to 15 sessions of a cognitive behavioral family therapy that will be developed during the course of this study and will address the following:~* parent-adolescent conflict~* adolescent development~* support and closeness~* behavioral activation~* response to adolescent negative affect~* relapse prevention~* suicide prevention, if necessary
Study: NCT04467853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-C18S cells
Description: Before treatment with LCAR-C18S cells, subjects will receive a conditioning regimen
Study: NCT00867919

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community-based treatment as usual
Description: Treatment as usual, which will most likely consist of 8 to 10 sessions of community-based depression treatment
Study: NCT03610217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constipation algorithm
Description: Patients with constipation will be randomized to receive bisacodyl or magnesium sulphate or polyethylene glycol or senna.If they fail the second line they will be crossed over to the other options randomly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin involvement algorithm
Description: Patients with skin involvement and modified Rodnan skin score \<32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option.~Patients with skin involvement and modified Rodnan skin score \>32 will be randomized to receive methotrexate plus mycophenolic acid or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain algorithm
Description: Patients with pain failing first line treatment with acetaminophen or celecoxib or ibuprofen will be randomized to receive pregabalin or duloxetine. Patients with skin involvement and modified Rodnan skin score \<32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option. In case they fail the second line they will be treated with medical marijuana.
Study: NCT00940134

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PYY 3-36
Description: 0.8 pmol/kg/min x 3 hours

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PYY 3-36
Description: 0.8 pmol/kg/min x 3 hours

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: 1.0 pmol/kg/min x 3 hours

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: 1.0 pmol/kg/min x 3 hours
Study: NCT01207856

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: specific cognitive rehabilitation
Description: Individual rehabilitation procedures will be focused on attention, executive functions, IPS and working memory. The program will be tailored to each patient cognitive status depending on the impairments identified during the initial assessment while maintaining a systematic work on attention and executive functions. A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed. Sessions will include varied exercises according to complexity and presentation modality, using computerized and paper-and-pencil tasks and metacognitive training. Work will be progressive, depending on the progresses achieved (increase complexity and intensity of the exercises according to success at the previous level of exercises).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non specific cognitive rehabilitation
Description: A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed by group composed to 5 patients
Study: NCT02805218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Study: NCT06077630

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention, observational study

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention, observational study
Study: NCT04146584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave Treatments
Description: The device used in this study will be the SofWave system manufactured by SofWave Medical ltd. The SofWave device is an ultrasonic system combined with an inherent cooling system that generates High Intensity non-focused Ultrasonic pulses (HIUS), causing a controlled thermal damage by elevating the temperature to 60-70°C in the dermis layer while sparing the epidermal layer using surface cooling. Each patient would receive 2 Sofwave treatments on the face and/or the neck.
Study: NCT03499041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3314814
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3314814
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3314814
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3314814
Description: Administered orally
Study: NCT00940134

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion
Description: saline infusion x 3 hours
Study: NCT00480454

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA 85A
Description: intradermal vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA 85A
Description: intradermal vaccine
Study: NCT01518192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: 100 mg bid; 15 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefuroxime axetil
Description: 500 mg bid; 15 days
Study: NCT03412422

Intervention type: DIAGNOSTIC_TEST
Intervention: fluid responsiveness assessment
Description: During the procedure, the investigator will be imaging one of the carotid arteries with ultrasound. In expiratory phase, four sets of three video loops will be recorded: before and after PLR and then before and after fluid challenge. There also will be noted hemodynamic parameters measured with PiCCO monitor. The fluid challenge is defined as administration of 500ml of crystalloid in less than 10 minutes. Later, another investigator, who will be blinded to other data, will measure the maximal and minimal diameter of CCA in each loop. The measurements will be averaged and eventually two values (maximal an minimal) from each set will be obtained.
Study: NCT00392444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally
Study: NCT04579055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-min STS test: adjusted
Description: Individually adjusted chair seat height of 90° knee joint flexion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1-min STS test: standardized
Description: Standardized chair seat height of 46 cm
Study: NCT02041351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: evaluate the activity of docetaxel on, metastatic lesions when measured after 4 cycles of chemotherapy
Study: NCT02096926

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 400 mg PO
Study: NCT01207856

Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT01087567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive insulin
Description: A weight-based basal bolus insulin regimen starting with 0.1 units/kg/day of Glargine and 4 units/meal of Glulisine.
Study: NCT01414647

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 g of strawberry, raspberry and cloudberry
Description: 100 g of strawberry puree, 100 g of frozen raspberries and 100 g frozen cloudberries were concumed daily for 8 weeks. Bilberry consumption was restricted.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 400 g of bilberry
Description: Equivalent amount to 400 g of fresh bilberries were consumed as 40 g of dried bilberries and as 200 g of frozen bilberries. Restriction of use of strawberries, raspberries and cloudberries were set.
Study: NCT01087567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Treatment in routine care will be based upon the 2009 ADA treatment recommendations.
Study: NCT00588783

Intervention type: DEVICE
Intervention: I-beam design
Description: This group will utilize tibial components with an I-beam design for total knee replacement.

Intervention type: DEVICE
Intervention: Cruciate design
Description: This group will utilize tibial components with cruciate designs for total knee replacement.
Study: NCT00190541

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesorectal excision with lateral lymph node dissection
Description: Mesorectal excision with lateral lymph node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesorectal excision without lateral lymph node excision
Description: Mesorectal excision without lateral lymph node excision
Study: NCT02660541

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Betafoam
Description: Comparison between 2 medical devices

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allevyn Silver Dressing
Description: Comparison between 2 medical devices
Study: NCT02135991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Getting To Outcomes
Description: These sites will receive written materials, training, and on site technical assistance to use the Getting To Outcomes process to implement Project CHOICE at their sites.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project CHOICE
Description: Sites will receive standard training for Project CHOICE.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project CHOICE
Description: Sites will receive standard training for Project CHOICE.
Study: NCT01609270

Intervention type: DEVICE
Intervention: CardioRoot graft
Description: prospective single arm multi-center study to evaluate CardioRoot grafts implanted in a thoracic position.
Study: NCT00827840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: 3mg to 12mg of Paliperidone ER once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 1 to 6 mg of risperidone once or twice a day
Study: NCT02061358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 3 mg
Description: Oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 10 mg
Description: Oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 30 mg
Description: Oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 90 mg
Description: Oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 180 mg
Description: Oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 360 mg
Description: Oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 720 mg
Description: Oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 1000 mg
Description: Oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, single dose
Study: NCT01329120

Intervention type: PROCEDURE
Intervention: Minimally invasive repair of pectus excavatum
Description: Minimally invasive surgical technique basically consisting of inserting one or more convex steel bars under the sternum through small bilateral incisions in the thoracic wall
Study: NCT01414647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control diet
Description: Control diet, ie. habitual diet with restriction of berry consumption was consumed for eight weeks
Study: NCT01329120

Intervention type: PROCEDURE
Intervention: Open surgical repair of pectus carinatum
Description: Open surgical removal the affected cartilages bilaterally and the excess cartilage over the sternum
Study: NCT00322868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily.
Study: NCT03290469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical whole genome sequencing (cWGS)
Description: Clinical Whole Genome Sequencing (cWGS) consists of the sequencing, analysis and interpretation of subjects samples and a return of the result to the ordering physician.
Study: NCT04271488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasurgratinib
Description: Tasurgratinib oral tablet.
Study: NCT04646447

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-serine
Description: L-Serine Arm L-serine is considered as GRAS (generally recognized as safe) by the FDA and has been approved as a normal food additive under CFR172.320.~All patients will receive the same L-serine dose treatment over 12 months. Arm: Experimental: L-Serine 250 mg / kg / day during the first two weeks. From week 3 to 52, 500 mg / kg / day. L-serine orally administered, divided into three doses a day.~The L-Serine will be manufactured, packaged, labeled and/or distributed by NUTRICIA or delegated contractors. It will be presented in a powdered form of 100 gr of the amino acid L-serine. For oral use.~Sufficient L-serine will be dispensed at home considering the dose according the weight of the patient.
Study: NCT01332240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography
Description: in order to stage the mediastinum
Study: NCT00121199

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01256476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin
Description: pitavastatin 4 mg once daily (QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pravastatin
Description: Pravastatin 40 mg once daily (QD)
Study: NCT02875678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-1431
Description: Single-dose ABX-1431
Study: NCT02061358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, single dose
Study: NCT02875678

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single-dose matching placebo
Study: NCT00225420

Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Description: Docetaxel will be administered per the designated cohort starting at 10 mg/m2 intravenously over 1 hour weekly for eight weeks, for a total of eight treatments.

Intervention type: DRUG
Group type: OTHER
Intervention: leuprolide acetate
Description: Leuprolide acetate will be administered at 22.5 mg IM and will be initiated 2 to 3 months prior to radiotherapy and chemotherapy with docetaxel.
Study: NCT02013869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow-I, a modern anaesthetic machine without a bag/below/gas reservoir for compression of insufflation gas
Description: Desflurane Dialed setting 18 % on the machine gas vaporized

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Asys, a anaesthetic machine with a bag/bellow for compression of gas to be insufflated
Description: Desflurane dialed 18% on the machine gas vaporized
Study: NCT00225420

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Description: The total dose will be 7800 cGy in 200 centigray (cGy) per fraction for a total of 39 treatments.
Study: NCT03673098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted 3RP
Description: The 3RP blends stress management principles, cognitive behavioral therapy, and positive psychology. The 3RP focuses on 3 major areas: (1) eliciting the relaxation response; (2) increasing stress awareness; and (3) promoting adaptive strategies. The adapted 3RP intervention consists of 10, 90-minute weekly group sessions. Content specific to older women living with HIV, including self-compassion exercises, was added to the intervention in the first phase of this study (open pilot).
Study: NCT05568485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation was applied to the group with rheumatism
Description: Telerehabilitation was applied to the group with rheumatism in 3 sessions a week for 24 weeks via a social texting program. The intervention sessions consisted of 10 minutes of dance therapy-authentic movement, 40 minutes of exercises, and 10 more minutes of dance therap
Study: NCT00005594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 2503
Description: Beginning dosage of ISIS 2503 is 6 mg/kg/day given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. This will be repeated for the first two weeks of every three-week treatment cycle.
Study: NCT04333836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Removable Clear Aligners
Description: 1. Plaster dental models will be poured from the rubber base impression.~2. Digital dental models will be created through scanning of plaster dental models.~3. Planning of the aligners will be done on 3 shape clear aligner studio®.~4. Aligners will be fabricated on 3d printed models using vacuum formers.~5. Anchorage reinforcement for posterior segments by using buccal miniscrews.~6. Patient will receive the first aligner and will be instructed to wear it full time (except during eating and brushing) for 2 weeks.~7. Patient will receive the following aligner after 2 weeks.~8. Follow up visits every 2 weeks until complete canine retraction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Removable Clear Aligners
Description: 1. Plaster dental models will be poured from the rubber base impression.~2. Digital dental models will be created through scanning of plaster dental models.~3. Planning of the aligners will be done on 3 shape clear aligner studio®.~4. Aligners will be fabricated on 3d printed models using vacuum formers.~5. Anchorage reinforcement for posterior segments by using buccal miniscrews.~6. Patient will receive the first aligner and will be instructed to wear it full time (except during eating and brushing) for 2 weeks.~7. Patient will receive the following aligner after 2 weeks.~8. Follow up visits every 2 weeks until complete canine retraction.
Study: NCT04209686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 1. Patients will receive treatment on Day 1 and 8 starting with cycle 2.~2. Paclitaxel (80 mg) will be administered IV on days 1 and 8 starting with cycle 2 (every 21 days).~3. Drug - Paclitaxel - 80mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 1. Patients will receive treatment on Day 1 and 8 starting with cycle 2.~2. Paclitaxel (80 mg) will be administered IV on days 1 and 8 starting with cycle 2 (every 21 days).~3. Drug - Paclitaxel - 80mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 1. Olaparib will be taken by mouth daily for 3 weeks (every 21 days).~2. Drug - 100 mg or 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 1. Olaparib will be taken by mouth daily for 3 weeks (every 21 days).~2. Drug - 100 mg or 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 1. Patients will receive treatment every 21 days.~2. Pembrolizumab (200 mg) will be administered IV on day 1 (every 21 days).~3. Drug - 200mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 1. Patients will receive treatment every 21 days.~2. Pembrolizumab (200 mg) will be administered IV on day 1 (every 21 days).~3. Drug - 200mg IV
Study: NCT00987792

Intervention type: DRUG
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Hospitalized patients receiving Avelox according to local drug information